Addendum
Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76
Report documents
-
Addendum
Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76
Dossier assessment
Indication:
Adult patients with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM)
Result of dossier assessment:
After addendum now: hint of considerable added benefit
Press releases
Considerable added benefit of mavacamten in obstructive hypertrophic cardiomyopathy
Due to unclear and missing information in the dossier, it had not yet been possible to prove an added benefit in a dossier assessment in 2023. The drug manufacturer provided additional data in the commenting procedure – with a positive result.
Additional information
Federal Joint Committee (G-BA)
2024-02-01 A G-BA decision was published.
Project details
- Project no.
- A23-132
- Commission
- Commission awarded on 12.12.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://dx.doi.org/10.60584/A23-132_en
Connected Projects
-
Dossier assessment
Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed